3d investors participates in Univercells Series D round
19 october 2022
Univercells is a global life sciences company with the mission of making biologics accessible to all. Using their combined expertise in scaling, production, and bioprocessing, Univercells finds new and sustainable ways to widen access to life-changing drugs. Univercells’ affiliate companies deploy innovations in infrastructure, drug substance manufacturing, equipment manufacturing, equipment design, training, and on-the-ground health services to drive down costs, shrink manufacturing footprints and meet the needs of the entire health value chain.
Headquartered in Jumet (Belgium), Univercells is supported by regional and national investors, as well as international investors active in vaccines and healthcare, such as the European Investment Bank and Global Health Investment Fund, among others.
As part of its €44 m Series D round in October 2022, 3d investors invested alongside existing and new shareholders such as Adjuvant, SFPI-FPIM and the Global Health Investment Corporation. The investment round is aimed at providing additional firing power to further accelerate the company’s promising growth plan for the coming years, which includes the global roll out of its RNA activities (through Quantoom) and further development of its CDMO activities in viral vectors (through Exothera).
The Univercells Group is fulfilling its global mission to make biologics available and accessible to all from its home base of Belgium, while continuing to explore paths for international expansion. In the meantime, the arrival of new national and international investors will help strengthen Univercells' ambition to achieve the developments it aims for in global health in the coming years.
Hugues Bultot, co-founder and CEO of the Univercells Group commented: “This first Series D closing is another step towards the realization of our mission to make biologics available to all and to successfully address health challenges during and between pandemics. We are committed to continue delivering breakthrough technologies and services that democratize the production of biologics and widen the access to life-changing drugs and vaccines. It is a pivotal moment to invest in biomanufacturing capabilities and we are looking forward to enabling our partners, from bio-innovators to governments, for the benefit of all”.
Nicolas Sneyers, Investment Director: “3d investors is proud to support Univercells in its quest to provide exponentially improved biomanufacturing equipment and services that will be used to provide more affordable healthcare throughout the world, making an important impact. We are impressed by the company’s vision, professionalism and traction across its different technologies and business models.”